Shots:

• Novartis will offer a portfolio of 15 generic and OTC medicines addressing the need of low- and lower-middle-income countries to treat patients with COVID-19 symptoms. The medicines will available governments- NGOs- and other institutional customers in up to 79 countries at zero-profit to support financially strained healthcare systems
• The Novartis’ COVID-19 portfolio aid to treat gastro-intestinal illness- acute respiratory symptoms- pneumonia- and septic shock. The portfolio will be offered in addition to the Novartis Access portfolio (on- and off-patent medicines against non-communicable diseases) via the local Novartis or Sandoz affiliate
• The COVID-19 portfolio includes Amoxicillin- Ceftriaxone- Clarithromycin- Colchicine- Dexamethasone- Dobutamine- Fluconazole- Heparin- Levofloxacin- Loperamide- Pantoprazole- Prednisone- Prednisolone- Salbutamol- Vancomycin

  Ref: Novartis | Image: Novartis